Rizatriptan
![]() |
|
Clinical data | |
---|---|
Trade names | Maxalt |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601109 |
Pregnancy category |
|
Routes of administration |
Oral |
ATC code | N02CC04 (WHO) |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 45% |
Protein binding | 14% |
Metabolism | by monoamine oxidase |
Biological half-life | 2–3 hours |
Excretion | 82% urine; 12% faeces |
Identifiers | |
|
|
CAS Number | 145202-66-0 ![]() |
PubChem (CID) | 5078 |
IUPHAR/BPS | 51 |
DrugBank | DB00953 ![]() |
ChemSpider | 4900 ![]() |
UNII | WR978S7QHH ![]() |
KEGG | D00675 ![]() |
ChEBI | CHEBI:48273 ![]() |
ChEMBL | CHEMBL905 ![]() |
ECHA InfoCard | 100.119.030 |
Chemical and physical data | |
Formula | C15H19N5 |
Molar mass | 269.345 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
![]() ![]() |
Rizatriptan (trade name Maxalt) is a 5-HT1 receptor agonist of the triptan class of drugs developed by Merck & Co. for the treatment of migraine headaches.[1] It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).
Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.
Rizatriptan is available only by prescription in Australia, Finland, the United States, Canada and New Zealand. Similarly, it is classed as a POM (Prescription Only Medicine) in the United Kingdom, Italy (as Rizaliv), France, Israel (as Rizalt), The Netherlands, Croatia and Spain (as Maxalt).
Contents
Indications[edit]
Rizatriptan is FDA-approved to treat acute migraine attacks with or without aura. It does not prevent future migraine attacks.[1] Rizatriptan is also used off-label to treat cluster headaches.
Contraindications[edit]
Adverse effects[edit]
Severe:
Atypical sensations: Ear, nose, and throat: |
Muscular: Neurological: Respiratory: Skin: Miscellaneous: |
Mechanism of action[edit]
Rizatriptan acts as an agonist at serotonin 5-HT1B and 5-HT1D receptors.[2] Like the other triptans sumatriptan and zolmitriptan, rizatriptan induces vasoconstriction—possibly by inhibiting the release of calcitonin gene-related peptide from sensory neurons in the trigeminal nerve.[2]
References[edit]
- ^ a b "Rizatriptan". MedlinePlus. U.S. National Library of Medicine.
- ^ a b Wellington, K; Plosker, G. L. (2002). "Rizatriptan: An update of its use in the management of migraine". Drugs. 62 (10): 1539–74. doi:10.2165/00003495-200262100-00007. PMID 12093318.
External links[edit]
- Maxalt website by Merck & Co.